DexCom, Inc. (NASDAQ:DXCM) Shares Sold by LGT Group Foundation

LGT Group Foundation decreased its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 50.5% in the fourth quarter, HoldingsChannel reports. The firm owned 9,262 shares of the medical device company’s stock after selling 9,465 shares during the quarter. LGT Group Foundation’s holdings in DexCom were worth $1,150,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Valley National Advisers Inc. increased its position in shares of DexCom by 73.0% in the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after buying an additional 103 shares in the last quarter. MV Capital Management Inc. boosted its stake in shares of DexCom by 99.3% in the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock worth $34,000 after acquiring an additional 138 shares during the last quarter. Washington Trust Advisors Inc. boosted its stake in shares of DexCom by 120.6% in the fourth quarter. Washington Trust Advisors Inc. now owns 353 shares of the medical device company’s stock worth $44,000 after acquiring an additional 193 shares during the last quarter. NBC Securities Inc. acquired a new stake in shares of DexCom in the third quarter worth approximately $47,000. Finally, Thompson Siegel & Walmsley LLC acquired a new stake in shares of DexCom in the third quarter worth approximately $48,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Stock Performance

Shares of DexCom stock opened at $128.37 on Friday. DexCom, Inc. has a 52 week low of $74.75 and a 52 week high of $142.00. The business’s fifty day simple moving average is $132.11 and its 200-day simple moving average is $119.96. The firm has a market cap of $51.05 billion, a PE ratio of 82.82, a price-to-earnings-growth ratio of 2.16 and a beta of 1.23. The company has a quick ratio of 2.53, a current ratio of 2.90 and a debt-to-equity ratio of 1.08.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.27 by $0.05. The business had revenue of $921.00 million for the quarter, compared to analyst estimates of $911.20 million. DexCom had a return on equity of 31.01% and a net margin of 16.82%. Equities analysts forecast that DexCom, Inc. will post 1.78 earnings per share for the current year.

Insider Activity at DexCom

In other DexCom news, CEO Kevin R. Sayer sold 81,007 shares of the company’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total transaction of $10,803,093.52. Following the sale, the chief executive officer now owns 333,526 shares in the company, valued at approximately $44,479,027.36. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other DexCom news, COO Jacob Steven Leach sold 14,639 shares of the company’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $134.41, for a total transaction of $1,967,627.99. Following the sale, the chief operating officer now owns 273,913 shares in the company, valued at approximately $36,816,646.33. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Kevin R. Sayer sold 81,007 shares of the company’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total value of $10,803,093.52. Following the sale, the chief executive officer now owns 333,526 shares in the company, valued at approximately $44,479,027.36. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 190,004 shares of company stock worth $25,610,270. 0.41% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of brokerages have recently issued reports on DXCM. StockNews.com raised DexCom from a “hold” rating to a “buy” rating in a research note on Wednesday. Raymond James lifted their price target on DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a research note on Friday, April 26th. Royal Bank of Canada initiated coverage on DexCom in a research note on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price objective on the stock. Canaccord Genuity Group boosted their price objective on DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a research note on Friday, April 26th. Finally, UBS Group boosted their price objective on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Two research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $141.67.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.